Valuation: Moderna, Inc.

Market Cap 27.09B 23.8B 22.07B 20.3B 38.34B 2,590B 39.17B 263B 103B 1,273B 102B 99.49B 4,400B P/E 2026 *
-7.88x
P/E 2027 * -14.3x
Enterprise Value 23.68B 20.81B 19.3B 17.74B 33.52B 2,265B 34.25B 230B 90.06B 1,113B 88.92B 86.98B 3,847B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 9.82x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-0.30%
1 week-15.99%
Current month-4.31%
1 month+34.26%
3 months+31.50%
6 months+98.02%
Current year+127.23%
1 week 65.54
Extreme 65.54
82.9
1 month 49.84
Extreme 49.8401
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Date Insider Type Main position Quantity % Market Cap.
07-04Free

Executive/Senior Manager

57,022 0.0144%
07-01Fiscal year

Chief Financial Officer

3,607 0.0009%
06-14Fiscal year

Chairperson

160,008 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
-1.85%-15.99%+99.20%-46.78% 27.09B
-0.22%+1.35%+16.79%-7.70% 67.61B
-0.63%-9.21%+37.82%+200.20% 51.6B
+0.36%+40.00%+40.00%+40.00% 43B
-1.26%-0.39%-49.63%-53.84% 40.94B
+4.96%-3.28%+55.75%-24.71% 29.4B
-2.12%-2.25%+66.54%+82.33% 23.32B
-0.67%+1.48%+10.61%+188.35% 19.92B
-2.12%-3.72%+61.37%+126.08% 16.91B
-3.27%+7.63%+78.78%+360.28% 16.84B
Average -1.02%-1.83%+41.72%+86.42% 33.66B
Weighted average by Cap. -0.72%-2.34%+33.36%+62.98%

Financials

2026 *2027 *
Net sales 2.09B 1.84B 1.71B 1.57B 2.96B 200B 3.03B 20.33B 7.96B 98.37B 7.86B 7.69B 340B 2.55B 2.24B 2.08B 1.91B 3.61B 244B 3.69B 24.77B 9.7B 120B 9.57B 9.36B 414B
Net income -3.41B -3B -2.78B -2.56B -4.83B -326B -4.93B -33.12B -12.97B -160B -12.81B -12.53B -554B -1.85B -1.63B -1.51B -1.39B -2.62B -177B -2.68B -17.97B -7.04B -86.94B -6.95B -6.8B -301B
Net Debt -3.41B -2.99B -2.78B -2.55B -4.82B -326B -4.93B -33.08B -12.95B -160B -12.79B -12.51B -553B -2.05B -1.8B -1.67B -1.54B -2.91B -196B -2.97B -19.94B -7.81B -96.47B -7.71B -7.54B -333B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
26-07-13 US$67.01 -1.85% 8,519,683
26-07-10 US$68.27 -10.83% 9,176,930
26-07-09 US$76.56 +3.74% 4,415,034
26-07-08 US$73.80 -7.48% 6,581,662
26-07-07 US$79.77 -2.48% 8,688,340
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
68.27USD
Average target price
48.26USD
Spread / Average Target
-29.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock